Why can Wilson disease neurological symptoms get worse when starting chelation?

Your doctor has warned you about something that sounds alarming: the medication meant to treat your Wilson disease might make your neurological symptoms worse before it makes them better. This is called paradoxical neurological worsening, and it is real, recognised, and — while deeply unsettling — something that specialists watch for specifically because it can be managed. Here is what happens, why it happens, and what questions to ask.

What does “paradoxical worsening” mean?

When a treatment makes the disease it is targeting temporarily worse, clinicians call this a paradoxical effect. In Wilson disease, this term refers to the appearance or aggravation of neurological symptoms — tremor, dysarthria (slurred speech), dystonia, difficulties with coordination or swallowing, psychiatric changes — after chelation therapy is started.¹ The paradox is that the drug is working in the liver (copper is being mobilised and excreted) while simultaneously causing harm in the nervous system.

This does not mean the treatment is wrong or that your doctor made an error. It is a known biological complication of the mechanism by which chelation works.

Why does it happen?

The most widely held explanation involves copper redistribution. Chelators like penicillamine bind copper in the body and promote its excretion through the urine. In the early phase of treatment, as copper is rapidly mobilised from liver stores, a transient surge of free copper enters the bloodstream before it is excreted.² The brain is vulnerable to this surge: copper crosses the blood-brain barrier, deposits in or redistributes within brain tissue, and this additional copper exposure can acutely worsen neurological function.

A secondary mechanism involves oxidative stress. Loose, unbound copper in the bloodstream generates damaging free radicals, and there is evidence from MRI and biochemical studies that the neurological worsening correlates with measurable increases in oxidative stress markers in the brain.³

Penicillamine appears to carry a substantially higher risk of paradoxical worsening than trientine. Studies have reported neurological deterioration in 10–50% of neurologically presenting patients who start penicillamine, with the wide range reflecting differences in how “worsening” is defined across studies.⁴ Trientine, and to an even greater extent zinc, appear to cause this complication less frequently, though it is not impossible with any copper-lowering agent. A 2023 editorial in the Journal of Hepatology by Litwin and colleagues argued that the field still lacks a consensus definition of what exactly constitutes early neurological worsening, which makes comparing studies difficult — but the phenomenon itself is not disputed.⁵

How long does it last?

This is the question patients most want answered, and the honest answer is: it varies, and it is not always reversible.

For most patients who experience mild-to-moderate worsening, neurological function stabilises and then begins to improve over weeks to months as total body copper burden falls. Patients who started on penicillamine and experienced worsening sometimes show better outcomes after being switched to trientine or zinc, though this switch itself requires careful management.⁶

The sobering reality is that a subset of patients — particularly those with severe neurological involvement at the time chelation is started — do not return to their pre-treatment baseline. In some published case series, permanent neurological decline following the initiation of chelation has been documented. This is why the timing and choice of initial therapy is a consequential decision that should ideally be made at a specialist centre with experience in Wilson disease.

Who is at highest risk?

The patients most likely to experience paradoxical worsening share several features:⁷

• Already have neurological symptoms at diagnosis — tremor, dysarthria, dystonia, or significant psychiatric change
• Starting penicillamine as the first chelator, rather than trientine or zinc
• Starting at a high initial dose rather than a low, gradual dose-escalation
• Younger age at presentation, though worsening has been reported across all ages

Patients with only liver disease and no neurological involvement at diagnosis appear to be at much lower risk.

What can be done to reduce the risk?

Specialist guidelines recommend several strategies to minimise the risk:⁸

1. Choose trientine or zinc for neurologically presenting patients. Many centres now favour trientine over penicillamine as the first-line agent when neurological symptoms are present, precisely because of the lower worsening risk.
2. Start low and titrate slowly. Beginning at a lower dose and increasing gradually gives the body time to adapt and may reduce the amplitude of copper redistribution.
3. Close monitoring in the first weeks. Neurological function should be formally assessed at every visit during the initiation phase so that any worsening is caught early and the treatment plan can be adjusted.
4. Consider zinc for specific patients. For patients with mild neurological involvement or those who are being switched after worsening on penicillamine, zinc may be used as a bridge.

A 2022 case series from India documented outcomes in children and adolescents with Wilson disease who experienced neurological worsening on penicillamine: many improved after switching to trientine, though the degree of recovery was variable and correlated with the severity of worsening.⁶

What to do if you notice worsening after starting treatment

If your symptoms worsen after starting chelation, contact your specialist promptly. Do not stop medication abruptly without medical guidance — stopping chelation suddenly carries its own risks. Instead, describe the change specifically:

• Which symptoms have worsened and by how much
• When the change started relative to beginning the medication
• Whether it is getting worse, stable, or beginning to improve

Your specialist will reassess your treatment — this might mean continuing on the current regimen with close monitoring, reducing the dose, switching to a different agent, or in some cases temporarily adjusting the approach.

For context on how chelation works and what the monitoring involves, see medications overview. If your question is specifically about stopping medication because you feel well, see also stopping medication when you feel fine.

A note on keeping perspective

It is hard to hear that the treatment might make things worse. But it is worth holding on to the longer view: the purpose of chelation is to remove the copper that is causing damage, and for the majority of patients — even those who experience early worsening — this goal is achieved over months to years. The worsening, when it happens, is a sign that the medication is active, not a sign that it is failing.

This post is patient education, not medical advice. Decisions about chelation — which agent to use, at what dose, with what monitoring — need to be made by a specialist who knows your full clinical picture. If you are worried about worsening after starting treatment, call your specialist rather than adjusting the medication on your own.

References